Edesa Biotech (EDSA) Preferred Stock Liabilities (2013 - 2014)
Edesa Biotech (EDSA) posted Preferred Stock Liabilities of $5.4 million for Q3 2014, down 21.69% sequentially from $6.8 million in Q3 2013, and down 21.69% YoY from $6.8 million in Q3 2013.
Edesa Biotech (EDSA) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Edesa Biotech has reported Preferred Stock Liabilities for 2 years, with the latest figure at $5.4 million in Q3 2014.
- Quarterly Preferred Stock Liabilities fell 21.69% year-over-year to $5.4 million in Q3 2014, while the trailing twelve-month figure through Aug 2014 was $5.4 million (down 21.69% YoY) and the FY2014 annual result came in at $5.4 million, down 21.69% from the prior year.
- Preferred Stock Liabilities eased to $5.4 million in Q3 2014 per EDSA's latest filing, from $6.8 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $6.8 million in Q3 2013 and troughed at $5.4 million in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2014 | 5.35 Mn |
| Aug 31, 2013 | 6.84 Mn |